We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Forehead Sensor Detects Hypoxemia Earlier

By HospiMedica staff writers
Posted on 10 Apr 2002
An adhesive forehead sensor displays changes in SpO2 faster than digit sensors during poor perfusion conditions, allowing clinicians to intervene sooner.

Called the Max-Fast, the sensor is based on the principle that arterial blood traveling from the heart reaches the head much sooner than the hands in poorly perfused patients. More...
The time difference between the forehead and finger sites can be significant. A study presented at the Society of Critical Care Medicine's 31st Critical Care Congress, in San Diego (CA, USA), found than the Max-Fast sensor responded to changes in SpO2 typically one to two minutes sooner than digit sensors for patients with low perfusion. The Max-Fast sensor also provides doctors with a more accurate picture of the magnitude of transient desaturations, says Nellcor (Pleasanton, CA, USA; www.nellcor.com), which developed the product. Also, the Max-Fast is the first sensor approved for use in mechanically ventilated patients.

The new sensor can be used with any OxiMax monitor from Nellcor, such as the Nellcor N-595 pulse oximeter. A digital memory chip embedded in the MaxFast sensor enables it to "talk” with the OxiMax monitor, where clinical information is displayed. The sensor's Event Report feature allows alarm history stored in the sensor to travel with the patient for quick assessment at various points of care throughout the hospital.

"We firmly believe that more centrally placed head sensors may offer significant advantage over finger sensors when monitoring patients with low perfusion or in situations where rapid detection of hypoxemia is critical,” said Donald E. Bebout, Ph.D.




Related Links:
Nellcor

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.